GlassScriptPhysician profile
Richard S Herdener
NPI 1457326365
$3,655.90
in general payments reported to CMS, 2019-2025
27 companies · $364 in 2025
The $364 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2020: $596 · 2021: $447 · 2022: $256 · 2023: $558 · 2024: $468 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,318 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,318.15 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $960.74 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $356.00 | 2019-2022 | |
| Pfizer INC. | $272.75 | 2019-2025 | |
| Janssen Biotech, INC. | $215.32 | 2019-2024 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $194.88 | 2021-2025 | |
| Amgen INC. | $191.57 | 2019-2020 | |
| Lilly USA, LLC | $186.79 | 2019-2022 | |
| Revance Therapeutics, INC. | $139.51 | 2024 | Daxi |
| Leo Pharma INC. | $136.55 | 2024-2025 | Adbry |
| Allergan, INC. | $131.37 | 2019-2021 | |
| Galderma Laboratories, L.P. | $128.37 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $120.14 | 2019-2022 | |
| Incyte Corporation | $116.36 | 2023 | Opzelura |
| Ucb, INC. | $84.79 | 2019-2025 | Bimzelx |
| Biofrontera INC. | $83.74 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $66.61 | 2023 | Vtama |
| Organogenesis INC. | $60.56 | 2019-2023 | Puraply |
| Novartis Pharmaceuticals Corporation | $40.45 | 2019 | |
| Almirall LLC | $36.08 | 2025 | Klisyri |
| Genzyme Corporation | $32.36 | 2019-2020 | |
| Celgene Corporation | $23.94 | 2019 | |
| Reprise Biomedical, INC. | $22.19 | 2025 | Miro3d |
| E.R. Squibb & Sons, L.L.C. | $16.25 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $15.78 | 2019 | |
| Genentech USA, INC. | $11.95 | 2019 | |
| Organon LLC | $10.85 | 2025 | Vtama |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Herdener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.